Short answer
LIFECORE BIOMEDICAL, INC. DE (LFCR) filed an 8-K current report with the SEC on March 16, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Q4 and full transition period results ending Dec 31, 2025 now reported by Lifecore Biomedical (LFCR).
LIFECORE BIOMEDICAL, INC. DE 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4 and full transition period results ending Dec 31, 2025 now reported by Lifecore Biomedical (LFCR)
- Press release (Exhibit 99.1) contains full financial details: primary source for revenue, margins, and earnings figures
- Transition period filing signals fiscal year-end change, which can affect YoY comparability
Item 7.01 · Regulation FD Disclosure
- Investor presentation published March 16, 2026 on LFCR's website: full details in Exhibit 99.2
- Reg FD disclosure ensures simultaneous public access; content may include guidance, strategy, or financial updates material to valuation
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other LIFECORE BIOMEDICAL, INC. DE 8-K filings
Get the next LFCR 8-K as it lands
Follow LFCR for push alerts, or ask the research agent what this filing means.